Alnylam Pharmaceuticals
ALNY
$143.71
Share price
-0.06%
Change (1 day)
-28.91%
Change (1 year)
Categories
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Alnylam Pharmaceuticals (ALNY) - Cash on Hand
Cash on Hand as of December 2023 : $2.43 B
According to Alnylam Pharmaceuticals
's latest financial reports the company has $2.43 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Alnylam Pharmaceuticals - Cash on Hand chart (from 2003 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $2.43 B | 11.27% |
| 2022-12-31 | $2.19 B | -9.98% |
| 2021-12-31 | $2.43 B | 29.94% |
| 2020-12-31 | $1.87 B | 22.02% |
| 2019-12-31 | $1.53 B | 41.69% |
| 2018-12-31 | $1.08 B | -35.87% |
| 2017-12-31 | $1.69 B | 169.72% |
| 2016-12-31 | $0.62 B | -41.99% |
| 2015-12-31 | $1.08 B | 55.09% |
| 2014-12-31 | $0.69 B | 183.36% |
| 2013-12-31 | $0.24 B | 100.2% |
| 2012-12-31 | $0.12 B | -16.11% |
| 2011-12-31 | $0.14 B | -37.2% |
| 2010-12-31 | $0.23 B | -17.15% |
| 2009-12-31 | $0.28 B | -34.62% |
| 2008-12-31 | $0.43 B | 10.37% |
| 2007-12-31 | $0.38 B | 79.48% |
| 2006-12-31 | $0.21 B | 171.57% |
| 2005-12-31 | $80 M | 73.74% |
| 2004-12-31 | $46.04 M | 98.53% |
| 2003-12-31 | $23.19 M | 49.85% |
| 2002-12-31 | $15.47 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $13.96 B | 472.36% | 🇨🇭 Switzerland |
 Sanofi SNY | $9.92 B | 306.99% | 🇫🇷 France |
 Regeneron Pharmaceuticals REGN | $10.84 B | 344.57% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | $1.67 B | -31.28% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | $30.78 M | -98.74% | 🇺🇸 USA |
 OPKO Health
OPK | $95.88 M | -96.07% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $3.22 B | 32.25% | 🇮🇱 Israel |
 Arrowhead Pharmaceuticals
ARWR | $0.22 B | -90.97% | 🇺🇸 USA |